Hyloris Pharmaceuticals (LTS:0AB6) Total Assets: €33.36 Mil (As of Dec. 2025)


LTS:0AB6 Hyloris Pharmaceuticals SA LTS:0AB6
63 GF Score
Price €4.53
GF Value €9.56
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Hyloris Pharmaceuticals Total Assets?

Hyloris Pharmaceuticals LTS:0AB6 63 Total Assets is €33.36 Mil as of Dec. 2025. GuruFocus rates LTS:0AB6 with a GF Score™ of 63/100 and a GF Value™ of €9.56 (Possible Value Trap). The stock has 3 warning signs investors should review.

Hyloris Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2025 was €33.36 Mil.

During the past 12 months, Hyloris Pharmaceuticals's average Total Assets Growth Rate was 10.40% per year. During the past 3 years, the average Total Assets Growth Rate was 4.30% per year. During the past 5 years, the average Total Assets Growth Rate was 25.70% per year.

During the past 10 years, Hyloris Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 73.40%. The lowest was 4.30%. And the median was 34.90%.

Total Assets is connected with ROA %. Hyloris Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2025 was -15.79%. Total Assets is also linked to Revenue through Asset Turnover. Hyloris Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2025 was 0.12.

Hyloris Pharmaceuticals  (LTS:0AB6) Total Assets Explanation

Total Assets is connected with ROA %.

Hyloris Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-5.558/( (37.052+33.357)/ 2 )
=-5.558/35.2045
=-15.79 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Hyloris Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=4.189/( (37.052+33.357)/ 2 )
=4.189/35.2045
=0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Hyloris Pharmaceuticals Total Assets Related Terms

Hyloris Pharmaceuticals Total Assets Historical Data

* Premium members only.

The historical data trend for Hyloris Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hyloris Pharmaceuticals Total Assets Chart

Hyloris Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 63.44 60.73 47.68 41.34 33.36

Hyloris Pharmaceuticals Semi-Annual Data
Dec16 Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.68 45.44 41.34 37.05 33.36
LTS:0AB6
63GF Score
Hyloris Pharmaceuticals SA LTS:0AB6
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hyloris Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Hyloris Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=26.475+6.882
=33.36

Hyloris Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=26.475+6.882
=33.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of €33.36 Mil mean?
Hyloris Pharmaceuticals (LTS:0AB6) has a Total Assets of €33.36 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Hyloris Pharmaceuticals and its competitors.
Is Hyloris Pharmaceuticals' Total Assets too high?
Hyloris Pharmaceuticals' current Total Assets is €33.36 Mil. Overall, Hyloris Pharmaceuticals has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hyloris Pharmaceuticals' Total Assets compare to VRTX and REGN?
Hyloris Pharmaceuticals' Total Assets of €33.36 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Hyloris Pharmaceuticals and its competitors. Hyloris Pharmaceuticals's current Total Assets is €33.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyloris Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals (LTS:0AB6) is currently considered Possible Value Trap. The stock's GF Value™ is €9.56, compared to a current price of €4.53 — trading 52.6% below its estimated fair value. The current Total Assets is €33.36 Mil. Hyloris Pharmaceuticals' overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Hyloris Pharmaceuticals (LTS:0AB6), the current Total Assets is €33.36 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hyloris Pharmaceuticals (LTS:0AB6) Overvalued in 2026?

Based on GuruFocus' analysis, Hyloris Pharmaceuticals stock appears to be undervalued. The current stock price of €4.53 is trading 52.6% below its estimated GF Value™ of €9.56. GuruFocus considers Hyloris Pharmaceuticals to be Possible Value Trap.

Key valuation signals for LTS:0AB6:

  • Total Assets: €33.36 Mil
  • GF Value™: €9.56 vs. price of €4.53 (52.6% below fair value)
  • GF Score™: 63/100 with 3 warning signs

No single metric tells the full story. See the LTS:0AB6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hyloris Pharmaceuticals Business Description

Other Exchanges 52U:GermanyHYL:Belgium
Address Boulevard Patience et Beaujonc No. 3/1, Liege, BEL, 4000
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.
63GF Score

Get the complete analysis for LTS:0AB6

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.53
Price
€9.56
GF Value